Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch® and ISETMenno Tamminga, Harry J.M. Groen|Cancers|2020Cited by 55
OA 05.05 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 TrialMyung‐Ju Ahn, D. Kim, Harry J.M. Groen et al.|Journal of Thoracic Oncology|2017Cited by 20
Microsieves for the detection of circulating tumor cells in leukapheresis product in non-small cell lung cancer patientsMenno Tamminga, Harry J.M. Groen|Translational Lung Cancer Research|2020Cited by 11
P1.01-001 Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK+ NSCLC in the ALTA TrialD. Ross Camidge, D. Kim, Marcello Tiseo et al.|Journal of Thoracic Oncology|2017Cited by 3